Condition
Nerve Sheath Tumors
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
P 1 (2)
Trial Status
Completed1
Not Yet Recruiting1
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04465643Phase 1CompletedPrimary
Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor
NCT07664397Phase 1Not Yet Recruiting
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
NCT01567787Not ApplicableWithdrawnPrimary
Proton Radiation Therapy for Spinal Tumors
Showing all 3 trials